ImpediMed

ImpediMed Equity Turnover

The Equity Turnover of ImpediMed (IPD.AX) as of Oct 24, 2026 is 1.43. In the previous year, Equity Turnover was 0.62 — a change of 131.07% (higher).

Equity Turnover

1.43

YoY

131.07%

Last updated:

Equity Turnover of ImpediMed is 2026 1.43 . Equity Turnover of ImpediMed was 2025 0.62 . It decreases by 131.07% higher compared to the previous year.

The ImpediMed Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2019
0.26 AUD
Jan 1, 2020
0.21 AUD
Jan 1, 2021
0.33 AUD
Jan 1, 2022
0.21 AUD
Jan 1, 2023
0.19 AUD
Jan 1, 2024
0.25 AUD
Jan 1, 2025
0.62 AUD
Jan 1, 2026
1.43 AUD
The ImpediMed Equity Turnover history
YEAREquity TurnoverYoY
1.43+131.07%
0.62+145.12%
0.25+35.92%
0.19-9.98%
0.21-37.19%
0.33+57.08%
0.21-20.31%
0.26+184.11%
0.09-5.50%
0.10+44.37%
0.07-51.15%
0.14-46.56%
0.26—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Equity Turnover of ImpediMed is 1.43 in 2026.

Equity Turnover of ImpediMed changed from 0.62 to 1.43, representing a 131.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ImpediMed

All Key Metrics — ImpediMed